| pubmed-article:169893 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:169893 | lifeskim:mentions | umls-concept:C0019208 | lld:lifeskim |
| pubmed-article:169893 | lifeskim:mentions | umls-concept:C0019409 | lld:lifeskim |
| pubmed-article:169893 | lifeskim:mentions | umls-concept:C2611689 | lld:lifeskim |
| pubmed-article:169893 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:169893 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:169893 | pubmed:dateCreated | 1976-1-2 | lld:pubmed |
| pubmed-article:169893 | pubmed:abstractText | KOH digestion of methyl-labeled poly(A)+ mRNA purified by (dT)-cellulose chromatography produced mononucleotide and multiple peaks of a large oligonucleotide (-6 to -8 charge) when separated on the basis of charge by Pellionex-WAX high-speed liquid chromatography in 7 M urea. Heat denaturation of the RNA before application to (dT)-cellulose was required to release contaminants (mostly 18S rRNA) that persisted even after repeated binding to (dT)-cellulose at room temperature. Analysis of the purified poly(A)+ mRNA by enzyme digestion, acid hydrolysis, and a variety of chromatographic techniques has shown that the monucleotide (53%) is due entirely to N6-methyladenosine. The large oligonucleotides (47%) were found to contain 7-methylguanosine and the 2'-0-methyl derivatives of all four nucleosides. No radioactivity was found associated with the poly(A) segment. Periodate oxidation of the mRNA followed by beta elimination released only labeled 7-methylguanine consistent with a blocked 5' terminus containing an unusual 5'-5' bond. Alkaline phosphatase treatment of intact mRNA had no effect on the migration of the KOH produced oligonucleotides on Pellionex-WAX. When RNA from which 7-methylguanine was removed by beta elimination was used for the phosphatase treatment, distinct dinucleotides (NmpNp) and trinucleotides (NmpNmpNp) occurred after KOH hydrolysis and Pellionex-WAX chromatography. Thus Novikoff hepatoma poly(A)+ mRNA molecules can contain either one or two 2'-0-methylnucleotides linked by a 5'-5' bond to a terminal 7-methylguanosine and the 2'-0-methylation can occur with any of the four nucleotides. The 5' terminus may be represented by m7G5'ppp5' (Nmp)lor2Np, a general structure proposed earlier as a possible 5' terminus for all eucaryotic mRNA molecules (Rottman, F., Shatkin, A., and Perry, R. (1974), Cell 3, 197). The composition analyses indicate that there are 3.0 N6-methyladenosine residues, 1.0 7-methylguanosine residue, and 1.7 2'-0-methylnucleoside residues per average mRNA molecule. | lld:pubmed |
| pubmed-article:169893 | pubmed:language | eng | lld:pubmed |
| pubmed-article:169893 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:169893 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:169893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:169893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:169893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:169893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:169893 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:169893 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:169893 | pubmed:issn | 0006-2960 | lld:pubmed |
| pubmed-article:169893 | pubmed:author | pubmed-author:RottmanF MFM | lld:pubmed |
| pubmed-article:169893 | pubmed:author | pubmed-author:FridericiK... | lld:pubmed |
| pubmed-article:169893 | pubmed:author | pubmed-author:DesrosiersR... | lld:pubmed |
| pubmed-article:169893 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:169893 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:169893 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:169893 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:169893 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:169893 | pubmed:pagination | 4367-74 | lld:pubmed |
| pubmed-article:169893 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-A... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-W... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-L... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-R... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-M... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-N... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-C... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-B... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-C... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-R... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-R... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-C... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-P... | lld:pubmed |
| pubmed-article:169893 | pubmed:meshHeading | pubmed-meshheading:169893-C... | lld:pubmed |
| pubmed-article:169893 | pubmed:year | 1975 | lld:pubmed |
| pubmed-article:169893 | pubmed:articleTitle | Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5' terminus. | lld:pubmed |
| pubmed-article:169893 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:169893 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:169893 | lld:pubmed |
